https://www.nasdaq.com/press-release/acelrx-pharmaceuticals-announces-publication-of-clinical-data-showing-reduced
https://www.nasdaq.com/press-release/acelrx-pharmaceuticals-announces-the-appointment-of-jill-broadfoot-to-its-board-of
https://www.nasdaq.com/press-release/acelrx-announces-%2414-million-registered-direct-common-stock-and-warrant-offering-2021
https://www.nasdaq.com/press-release/acelrx-pharmaceuticals-to-acquire-lowell-therapeutics-and-reports-third-quarter-2021
https://www.nasdaq.com/press-release/acelrx-to-host-third-quarter-2021-financial-results-call-and-webcast-on-november-15
https://www.nasdaq.com/press-release/acelrx-pharmaceuticals-to-participate-in-two-september-investor-conferences-2021-09
https://www.nasdaq.com/press-release/study-results-announced-during-award-winning-presentation-on-the-effect-of-sufentanil
https://www.nasdaq.com/press-release/presentation-on-the-effect-of-the-administration-of-sufentanil-sublingual-tablet-on
https://www.nasdaq.com/press-release/acelrx-pharmaceuticals-reports-second-quarter-2021-financial-results-2021-08-16
https://www.nasdaq.com/press-release/acelrx-to-host-second-quarter-2021-financial-results-call-and-webcast-on-august-16
https://www.nasdaq.com/press-release/acelrx-enters-into-licensing-agreement-for-dzuveor-in-europe-and-in-licensing
https://www.nasdaq.com/press-release/acelrx-announces-agreement-with-fda-addressing-the-warning-letter-received-for
https://www.nasdaq.com/press-release/rapid-discharge-with-minimal-pacu-opioids-was-key-message-during-presentation-of
https://www.nasdaq.com/press-release/presentation-on-the-use-of-dsuviar-for-plastic-surgery-procedures-selected-for-best
https://www.nasdaq.com/press-release/acelrx-announces-an-investigator-initiated-study-of-dsuviar-in-the-emergency
https://www.nasdaq.com/press-release/acelrx-pharmaceuticals-reports-first-quarter-2021-financial-results-2021-05-17
https://www.nasdaq.com/press-release/study-of-dsuviar-showing-significant-reduction-in-postoperative-opioids-and-better
https://www.nasdaq.com/press-release/acelrx-to-host-first-quarter-2021-financial-results-call-and-webcast-on-may-17-2021
https://www.nasdaq.com/press-release/acelrx-announces-an-investigator-initiated-study-of-dsuviar-for-use-in-same-day-total
https://www.nasdaq.com/press-release/acelrx-announces-an-investigator-initiated-study-of-dsuviar-in-patients-taking
https://www.nasdaq.com/press-release/acelrx-pharmaceuticals-announces-appointment-of-marina-bozilenko-to-the-board-of
https://www.nasdaq.com/press-release/acelrx-pharmaceuticals-announces-clinical-data-reporting-high-ratings-for-healthcare
https://www.nasdaq.com/press-release/acelrx-announces-presentation-and-fireside-chat-at-the-benzinga-biotech-small-cap
https://www.nasdaq.com/press-release/acelrx-pharmaceuticals-reports-fourth-quarter-and-full-year-2020-financial-results
https://www.nasdaq.com/press-release/acelrx-to-host-fourth-quarter-and-full-year-2020-financial-results-call-and-webcast
https://www.nasdaq.com/press-release/acelrx-announces-an-investigator-initiated-study-of-dsuviar-in-patients-undergoing
https://www.nasdaq.com/press-release/acelrx-announces-pricing-of-%2427.5-million-public-offering-of-common-stock-2021-01-20
https://www.nasdaq.com/press-release/acelrx-announces-underwritten-public-offering-of-common-stock-2021-01-19
https://www.nasdaq.com/press-release/acelrx-announces-an-investigator-initiated-study-of-dsuviar-in-cardiac-surgery
https://www.nasdaq.com/press-release/acelrx-announces-year-end-2020-metrics-and-review-of-2020-achievements-2021-01-14
https://www.nasdaq.com/press-release/acelrx-pharmaceuticals-announces-publication-of-clinical-data-on-decreased
https://www.nasdaq.com/press-release/acelrx-announces-%2410-million-registered-direct-common-stock-offering-2020-12-10
https://www.nasdaq.com/press-release/acelrx-pharmaceuticals-to-present-at-ld-micro-main-event-2020-12-09
https://www.nasdaq.com/press-release/acelrx-pharmaceuticals-announces-partnership-with-the-national-rural-health
https://www.nasdaq.com/press-release/acelrx-pharmaceuticals-announces-commentary-in-practical-pain-management-on
https://www.nasdaq.com/press-release/acelrx-pharmaceuticals-to-present-at-credit-suisse-29th-annual-virtual-healthcare
https://www.nasdaq.com/press-release/acelrx-pharmaceuticals-reports-third-quarter-2020-financial-results-2020-11-05
https://www.nasdaq.com/press-release/acelrx-to-host-third-quarter-2020-financial-results-call-and-webcast-on-thursday
https://www.nasdaq.com/press-release/acelrx-to-host-virtual-kol-event-on-perioperative-use-of-dsuviar-2020-09-29
https://www.nasdaq.com/press-release/acelrx-awarded-u.s.-army-contract-for-dsuviar-2020-09-22
https://www.nasdaq.com/press-release/acelrx-announces-dsuviar-added-to-the-u.s.-department-of-defenses-joint-deployment
https://www.nasdaq.com/press-release/acelrx-pharmaceuticals-to-present-at-two-upcoming-conferences-2020-09-10
https://www.nasdaq.com/press-release/ld-micro-360-companies-set-to-present-this-week-2020-08-31
https://www.nasdaq.com/press-release/acelrx-announces-an-investigator-initiated-study-of-dsuviar-in-orthopedic-patients-in
https://www.nasdaq.com/press-release/acelrx-pharmaceuticals-announces-publication-of-clinical-data-on-reduced-opioid-use
https://www.nasdaq.com/press-release/acelrx-pharmaceuticals-reports-second-quarter-2020-financial-results-2020-08-10
https://www.nasdaq.com/press-release/acelrx-to-host-second-quarter-2020-financial-results-call-and-webcast-on-monday
https://www.nasdaq.com/press-release/acelrx-announces-exclusive-distribution-and-promotion-partnership-for-dsuviar-2020-07
https://www.nasdaq.com/press-release/acelrx-announces-%2410-million-common-stock-offering-priced-at-the-market-2020-07-23
https://www.nasdaq.com/press-release/acelrx-pharmaceuticals-announces-it-will-not-further-revise-its-offer-to-acquire
https://www.nasdaq.com/press-release/acelrx-pharmaceuticals-to-present-at-the-jefferies-virtual-healthcare-conference-2020
https://www.nasdaq.com/press-release/acelrx-pharmaceuticals-announces-revised-merger-agreement-with-tetraphase-2020-05-29
https://www.nasdaq.com/press-release/acelrx-pharmaceuticals-announces-revised-merger-agreement-with-tetraphase-2020-05-27
https://www.nasdaq.com/press-release/acelrx-pharmaceuticals-reports-first-quarter-2020-financial-results-2020-05-11
https://www.nasdaq.com/press-release/acelrx-to-host-first-quarter-2020-financial-results-call-and-webcast-on-monday-may
https://www.nasdaq.com/press-release/acelrx-announces-dsuviar-milestone-c-approval-and-provides-business-update-2020-04-30
https://www.nasdaq.com/press-release/acelrx-pharmaceuticals-reports-fourth-quarter-and-full-year-2019-financial-results
https://www.nasdaq.com/press-release/acelrx-pharmaceuticals-to-acquire-tetraphase-pharmaceuticals-2020-03-16
https://www.nasdaq.com/press-release/acelrx-to-announce-fourth-quarter-2019-results-on-monday-march-16th-2020-2020-03-11
https://www.nasdaq.com/press-release/acelrx-announces-confirmed-timing-of-department-of-defense-milestone-c-meeting-for
https://www.nasdaq.com/press-release/acelrx-announces-agreement-for-an-investigator-initiated-study-of-dsuviar-in-patients
https://www.nasdaq.com/press-release/acelrx-announces-year-end-2019-metrics-and-provides-corporate-updates-2020-01-13
https://www.nasdaq.com/press-release/acelrx-pharmaceuticals-announces-publication-analyzing-pooled-dosing-and-efficacy
https://www.nasdaq.com/press-release/acelrx-pharmaceuticals-reports-third-quarter-2019-financial-results-2019-11-06
https://www.nasdaq.com/press-release/acelrx-pharmaceuticals-to-present-at-credit-suisse-28th-annual-healthcare-conference
https://www.nasdaq.com/press-release/acelrx-to-announce-third-quarter-2019-results-and-provide-an-update-on-the-companys
https://www.nasdaq.com/press-release/dr.-tj-gan-to-present-at-the-2019-annual-meeting-of-the-american-society-of
https://www.nasdaq.com/press-release/acelrx-pharmaceuticals-selected-to-present-at-the-2019-military-health-system
https://www.nasdaq.com/press-release/acelrx-pharmaceuticals-reports-second-quarter-2019-financial-results-2019-08-05
https://www.nasdaq.com/press-release/acelrx-to-announce-second-quarter-2019-results-and-provide-an-update-on-the-companys
https://www.nasdaq.com/press-release/acelrx-added-to-the-russell-2000r-and-3000r-indexes-2019-07-01
https://www.nasdaq.com/press-release/acelrx-announce-first-quarter-2019-results-and-provide-update-companys-business
